Slide One
Slide Two
Slide Three

So far, about a hundred clinical trials have been done, and the results are very promising.

"With all the phase 1 trials we are doing, the technology is working just like we predicted, and we are very encouraged with the results that we are seeing," Valluri said.

They are looking to get in about 30 more patients for this round of clinical trials, for what they're calling the reactive phase.

"Soon, in about six months, we will be using this is a different type of trialing, which will be in a predictive modality," Claudio said.

They are moving toward what's called 510K clearance with the food and drug administration to hopefully become even more mainstream in the coming months. The goal is to have that happen in the next year.

"We are very proud of this, and we are working diligently to be able to make it available to our cancer population and hopefully the whole United States in the future," Claudio said.

PO BOX 20065 | Charleston, WV 25362 | (304) 546-5500